RNLX (renalytix.com) Kapitalisasi Akuntansi

Renalytix Plc (RNLX) develops kidney diagnostics, yet faces uncertainty regarding insurance reimbursements and inertia among medical professionals. High capital expenditure and the threat of Medicare denial hinder profitability, while low clinic demand for tests fails to cover operating expenses, keeping the metric at -0.00. This price action is reflected in the daily price chart of the asset's value on the GURU.Markets platform.

Renalytix Plc is developing AI-driven kidney diagnostics by combining internal proprietary algorithms with cloud-based data outsourcing. Book capitalization measures the difference between all assets and liabilities, reflecting the actual equity value of the business; analyzing the book equity chart allows an investor to identify stock overvaluation relative to net assets and avoid purchasing an overpriced asset.